Other features such as gender, multifocality, thyroiditis, presence of thyroid nodules, and mutation status of KRAS, BRAF, and TERT did not significantly differ between the high- and low-risk groups in this validation set. The gene discussed is BRAF; the disease is thyroid gland disorder.